Corbus Pharmaceuticals Holdings (CRBP) Accumulated Expenses (2013 - 2025)

Corbus Pharmaceuticals Holdings' Accumulated Expenses history runs 13 years deep, the most recent figure standing at $16.8 million for Q4 2025.

• In Q4 2025, Accumulated Expenses rose 210.43% year-over-year to $16.8 million; the TTM figure through Dec 2025 stood at $16.8 million (up 210.43% YoY), while the FY2025 annual figure was $16.8 million, up 210.43% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $16.8 million, up from $12.6 million in the prior quarter.
• The five-year high for Accumulated Expenses was $17.7 million in Q1 2021, with the low at $4.7 million in Q2 2022.
• The 5-year median for Accumulated Expenses is $8.5 million (2024), against an average of $9.5 million.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses sank 69.02% in 2022, then soared 210.43% in 2025.
• Corbus Pharmaceuticals Holdings' Accumulated Expenses stood at $10.1 million in 2021, then sank by 40.56% to $6.0 million in 2022, then surged by 83.86% to $11.0 million in 2023, then tumbled by 50.81% to $5.4 million in 2024, then jumped by 210.43% to $16.8 million in 2025.
• Business Quant data shows CRBP's Accumulated Expenses at $16.8 million in Q4 2025, $12.6 million in Q3 2025, and $7.6 million in Q2 2025.